ALXN has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
ALXN has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
As of today (2024-04-25), Alexion Pharmaceuticals's current share price is $182.50. Alexion Pharmaceuticals's E10 for the quarter that ended in Mar. 2021 was $2.94. Alexion Pharmaceuticals's Shiller PE Ratio for today is 62.07.
The historical rank and industry rank for Alexion Pharmaceuticals's Shiller PE Ratio or its related term are showing as below:
During the past years, Alexion Pharmaceuticals's highest Shiller PE Ratio was 98.74. The lowest was 30.46. And the median was 59.73.
ALXN's Shiller PE Ratio is not rankedE10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years.
Alexion Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2021 was $2.860. Add all the adjusted EPS for the past 10 years together and divide 10 will get our E10, which is $2.94 for the trailing ten years ended in Mar. 2021.
The historical data trend for Alexion Pharmaceuticals's Shiller PE Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alexion Pharmaceuticals Quarterly Data | ||||||||||||||||||||
Jun16 | Sep16 | Dec16 | Mar17 | Jun17 | Sep17 | Dec17 | Mar18 | Jun18 | Sep18 | Dec18 | Mar19 | Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | |
Shiller PE Ratio | Get a 7-Day Free Trial | 33.81 | 52.50 | 47.30 | 59.58 | 52.27 |
For the Biotechnology subindustry, Alexion Pharmaceuticals's Shiller PE Ratio, along with its competitors' market caps and Shiller PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Alexion Pharmaceuticals's Shiller PE Ratio distribution charts can be found below:
* The bar in red indicates where Alexion Pharmaceuticals's Shiller PE Ratio falls into.
For Shiller PE Ratio, the earnings of the past 10 years are inflation-adjusted and averaged. The result is used for P/E calculation. Since it looks at the average over the last 10 years, the Shiller PE Ratio is also called PE10.
The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The same calculation is applied here to individual companies.
Alexion Pharmaceuticals's Shiller PE Ratio for today is calculated as
Shiller PE Ratio | = | Share Price | / | E10 |
= | 182.50 | / | 2.94 | |
= | 62.07 |
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alexion Pharmaceuticals's E10 for the quarter that ended in Mar. 2021 is calculated as:
For example, Alexion Pharmaceuticals's adjusted earnings per share data for the three months ended in Mar. 2021 was:
Adj_EPS | = | Earnings per Share (Diluted) | / | CPI of Mar. 2021 (Change) | * | Current CPI (Mar. 2021) |
= | 2.86 | / | 111.7544 | * | 111.7544 | |
= | 2.860 |
Current CPI (Mar. 2021) = 111.7544.
Alexion Pharmaceuticals Quarterly Data
Earnings per Share (Diluted) | CPI | Adj_EPS | |
201106 | 0.180 | 95.235 | 0.211 |
201109 | 0.340 | 95.727 | 0.397 |
201112 | 0.250 | 95.213 | 0.293 |
201203 | 0.230 | 96.783 | 0.266 |
201206 | 0.180 | 96.819 | 0.208 |
201209 | 0.460 | 97.633 | 0.527 |
201212 | 0.400 | 96.871 | 0.461 |
201303 | 0.410 | 98.209 | 0.467 |
201306 | 0.480 | 98.518 | 0.544 |
201309 | 0.470 | 98.790 | 0.532 |
201312 | -0.100 | 98.326 | -0.114 |
201403 | 0.790 | 99.695 | 0.886 |
201406 | 0.830 | 100.560 | 0.922 |
201409 | 0.880 | 100.428 | 0.979 |
201412 | 0.760 | 99.070 | 0.857 |
201503 | 0.450 | 99.621 | 0.505 |
201506 | 0.830 | 100.684 | 0.921 |
201509 | -0.810 | 100.392 | -0.902 |
201512 | 0.290 | 99.792 | 0.325 |
201603 | 0.410 | 100.470 | 0.456 |
201606 | 0.530 | 101.688 | 0.582 |
201609 | 0.420 | 101.861 | 0.461 |
201612 | 0.410 | 101.863 | 0.450 |
201703 | 0.750 | 102.862 | 0.815 |
201706 | 0.730 | 103.349 | 0.789 |
201709 | 0.350 | 104.136 | 0.376 |
201712 | 0.130 | 104.011 | 0.140 |
201803 | 1.110 | 105.290 | 1.178 |
201806 | -2.050 | 106.317 | -2.155 |
201809 | 1.470 | 106.507 | 1.542 |
201812 | -0.200 | 105.998 | -0.211 |
201903 | 2.610 | 107.251 | 2.720 |
201906 | 2.040 | 108.070 | 2.110 |
201909 | 2.080 | 108.329 | 2.146 |
201912 | 4.000 | 108.420 | 4.123 |
202003 | 2.500 | 108.902 | 2.565 |
202006 | -4.840 | 108.767 | -4.973 |
202009 | 2.620 | 109.815 | 2.666 |
202012 | 2.420 | 109.897 | 2.461 |
202103 | 2.860 | 111.754 | 2.860 |
Add all the adjusted EPS together and divide 10 will get our E10.
Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.
Compared with the regular PE Ratio, which works poorly for cyclical businesses, the Shiller PE Ratio smoothed out the fluctuations of profit margins during business cycles. Therefore it is more accurate in reflecting the valuation of the company.
If a company has consistent business performance, the Shiller PE Ratio should give similar results to regular PE Ratio.
Compared with the PS Ratio, the Shiller PE Ratio makes the comparison between different industries more meaningful.
Shiller PE Ratio assumes that over the long term, businesses and profitability revert to their means. If a company's business model does not work in the future compared with the past, Shiller PE Ratio and PS Ratio will give false valuations.
Thank you for viewing the detailed overview of Alexion Pharmaceuticals's Shiller PE Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.
Daniel Bazarko | officer: SVP, Controller, CAO | C/O ALEXION PHARMACEUTICALS, INC. 121 SEAPORT BOULEVARD BOSTON MA 02210 |
Tanisha Carino | officer: EVP & CCAO | C/O ALEXION PHARMACEUTICALS, INC., 121 SEAPORT BOULEVARD, BOSTON MA 02210 |
Anne-marie Law | officer: EVP, Chief Experience Officer | C/O BAXALTA INCORPORATED, 1200 LAKESIDE DRIVE, BANNOCKBURN IL 60015 |
Brian Goff | officer: EVP & Chief Commercial Officer | C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510 |
John J Orloff | officer: EVP, Research & Development | C/O BAXALTA INCORPORATED 1200 LAKESIDE DRIVE BANNOCKBURN IL 60015 |
Indrani Lall Franchini | officer: EVP, Chief Compliance Officer | C/O ALEXION PHARMACEUTICALS, INC, 100 COLLEGE STREET, NEW HAVEN CT 06510 |
John T Mollen | director | 176 SOUTH STREET HOPKINTON MA 01748 |
David R Brennan | director | C/O INSMED INCORPORATED, 10 FINDERNE AVENUE, BRIDGEWATER NJ 08807 |
Baker Bros. Advisors (gp) Llc | director | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
L.p. 667, | director | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Andreas Rummelt | director | C/O ALEXION PHARMACEUTICALS, INC. 352 KNOTTER DRIVE CHESHIRE CT 06410 |
Francois Nader | director | 550 HILLS DRIVE, BEDMINSTER NJ 07921 |
Baker Brothers Life Sciences Lp | director | 860 WASHINGTON STREET, 3RD FLOOR, NEW YORK NY 10014 |
Deborah Dunsire | director | C/O ULTRAGENYX PHARMACEUTICAL INC., 60 LEVERONI COURT, NOVATO CA 94949 |
Judith A Reinsdorf | director | C. R. BARD, INC., 730 CENTRAL AVENUE, MURRAY HILL NJ 07974 |
From GuruFocus
By Business Wire Business Wire • 06-07-2021
By Business Wire Business Wire • 07-15-2021
By GuruFocus Research GuruFocus Editor • 05-18-2021
By PRNewswire PRNewswire • 03-01-2021
By Business Wire Business Wire • 06-11-2021
By GuruFocus Research GuruFocus Editor • 07-12-2021
By Business Wire Business Wire • 03-05-2021
By GuruFocus Research GuruFocus Editor • 05-19-2021
By Business Wire Business Wire • 05-12-2021
By Business Wire Business Wire • 05-12-2021